Research & Development

AP (arbaclofen placarbil)

Program	Pre-Clinical	Phase 1	Phase 2	Phase 3	NDA Filed	Partner
Arbaclofen Placarbil						

Discovered by XenoPort, arbaclofen placarbil (AP) is a patented, oral new chemical entity that utilizes naturally-occurring, high-capacity nutrient transporters in the gastrointestinal tract to generate active, efficient absorption into the body. Once absorbed, AP is rapidly converted to the R-isomer of baclofen, a generic drug that is racemic (a mixture of the R- and S-isomer). Baclofen is a selective GABA-B agonist.

In May 2014, XenoPort entered into a license agreement with Reckitt Benckiser Pharmaceuticals, Inc.(RBP), granting it exclusive, world-wide rights for the development and commercialization of AP for all indications. XenoPort has first right of negotiation with RBP to collaborate on the development and commercialization of AP for non-addiction indications.

TOP

Research & Development Home
XenoPort Pipeline
XP23829
Arbaclofen Placarbil
XP21279
Our Technology

Clinical Trial Information

The U.S. National Institutes of Health provides a Web site of many current and past clinical trials. To view information about XenoPort's clinical trials, please go to www.clinicaltrials.gov.

This icon indicates a link to an external site.